Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q

NCT01081431 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

91

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Lenalidomide

Sponsor

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Collaborators

[object Object]